INO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Inovio Pharmaceuticals Inc (INO) is not a strong buy for a beginner, long-term investor at this time. The stock faces significant legal challenges, weak financial performance, and lacks positive momentum or trading signals. While the technical indicators are neutral, the absence of strong catalysts and the presence of negative news sentiment make it prudent to hold off on investing in this asset for now.
The MACD histogram is positive at 0.0306, indicating slight bullish momentum, but it is contracting. RSI is neutral at 58.112, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key support and resistance levels are S1: 1.59, Pivot: 1.771, and R1: 1.952, with the current price close to the pivot level.
NULL identified. The technical indicators are neutral, and there are no recent positive developments or trading signals.
The company faces multiple class action lawsuits alleging false statements about manufacturing deficiencies and regulatory delays. Negative news sentiment dominates, with no positive developments to offset these issues. Financial performance remains weak, with negative net income and declining EPS.
In Q3 2025, revenue was stagnant at $0, with no YoY growth. Net income improved by 80.79% YoY but remains significantly negative at -$45,496,672. EPS dropped by -2.25% YoY to -0.87, reflecting continued challenges. Gross margin remains at 100% but is not indicative of operational success given the lack of revenue.
No recent analyst rating or price target changes are available. Wall Street sentiment appears neutral to negative, with no strong buy recommendations.
